Emerging evidence suggests that the timing of microglial activity is crucial for amyloid pathology: TREM2 deficiency was found to ameliorate amyloid pathology early but exacerbate it late in the APPPS1-21 AD model mice [89]. The gene discussed is TREM2; the disease is amyloidosis.